1 report

FDA Advisory Committee recommended approval for biosimilar filgrastim: In January 2015, the FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of Sandoz investigational biosimilar filgrastim in the US for use in all indications included in the reference product'

  • Clinical Trial
  • Diagnostics
  • Healthcare
  • Polyclonal Antibody
  • GlobalData's company